Logo image of ZFGN

Zafgen Inc (ZFGN) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:ZFGN -

0.99
-0.17 (-14.66%)
Last: 5/28/2020, 8:00:10 PM
0.97
-0.02 (-2.02%)
After Hours: 5/28/2020, 8:00:10 PM

ZFGN Key Statistics, Chart & Performance

Key Statistics
Market Cap37.10M
Revenue(TTM)N/A
Net Income(TTM)-35.89M
Shares37.47M
Float12.17M
52 Week High1.88
52 Week Low0.62
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.81
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A


ZFGN short term performance overview.The bars show the price performance of ZFGN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20

ZFGN long term performance overview.The bars show the price performance of ZFGN in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40

The current stock price of ZFGN is 0.99 null. In the past month the price increased by 26.16%. In the past year, price decreased by -45.9%.

Zafgen Inc / ZFGN Daily stock chart

About ZFGN

Company Profile

Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts.

Company Info

Zafgen Inc

3 Center Plaza Suite 610

BOSTON MA 02108

CEO: Jeffrey Hatfield

Phone: 617-622-4003

Zafgen Inc / ZFGN FAQ

What does ZFGN do?

Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts.


What is the current price of ZFGN stock?

The current stock price of ZFGN is 0.99 null. The price decreased by -14.66% in the last trading session.


Does ZFGN stock pay dividends?

ZFGN does not pay a dividend.


What is the ChartMill rating of Zafgen Inc stock?

ZFGN has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


ZFGN Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to ZFGN. When comparing the yearly performance of all stocks, ZFGN is a bad performer in the overall market: 88.88% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ZFGN Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ZFGN. Both the profitability and financial health of ZFGN have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ZFGN Financial Highlights

Over the last trailing twelve months ZFGN reported a non-GAAP Earnings per Share(EPS) of -0.81. The EPS increased by 52.91% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -48.7%
ROE N/A
Debt/Equity 0.26
Chartmill High Growth Momentum
EPS Q2Q%71.43%
Sales Q2Q%N/A
EPS 1Y (TTM)52.91%
Revenue 1Y (TTM)N/A

ZFGN Forecast & Estimates


Analysts
Analysts60
Price TargetN/A
EPS Next Y30.84%
Revenue Next YearN/A

ZFGN Ownership

Ownership
Inst Owners70.43%
Ins Owners26.62%
Short Float %N/A
Short RatioN/A